Geron Announces Conference Call to Discuss Second Quarter Financial Results and Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq:GERN) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, July 28, 2011, after the closing of the equity market. David L. Greenwood, Geron’s President and Chief Executive Officer, will host a conference call for analysts and investors on Friday, July 29, 2011 at 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time.

Participants can access the conference call live via telephone by dialing 800-591-6944 (U.S.); 617-614-4910 (international). The passcode is 38893153. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=67323&eventID=4162511. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through August 30, 2011.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury. For more information, visit www.geron.com.



CONTACT:

Geron Corporation
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.